Advisors Asset Management Inc. Acquires New Shares in The Chemours Company (NYSE:CC)

Advisors Asset Management Inc. bought a new position in shares of The Chemours Company (NYSE:CC) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 95,402 shares of the specialty chemicals company’s stock, valued at approximately $1,939,000. Advisors Asset Management Inc. owned approximately 0.06% of Chemours as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Burney Co. grew its holdings in shares of Chemours by 0.3% during the first quarter. Burney Co. now owns 197,046 shares of the specialty chemicals company’s stock worth $5,174,000 after buying an additional 601 shares in the last quarter. KBC Group NV raised its holdings in Chemours by 19.5% in the 3rd quarter. KBC Group NV now owns 4,468 shares of the specialty chemicals company’s stock valued at $91,000 after acquiring an additional 728 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Chemours by 166.9% during the 3rd quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock worth $26,000 after purchasing an additional 731 shares during the period. Arizona State Retirement System boosted its holdings in shares of Chemours by 2.1% during the second quarter. Arizona State Retirement System now owns 41,657 shares of the specialty chemicals company’s stock worth $940,000 after purchasing an additional 863 shares during the last quarter. Finally, New Covenant Trust Company N.A. purchased a new stake in shares of Chemours in the first quarter valued at $29,000. Institutional investors and hedge funds own 76.26% of the company’s stock.

Analyst Upgrades and Downgrades

CC has been the topic of a number of research analyst reports. Royal Bank of Canada decreased their price target on Chemours from $28.00 to $25.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. JPMorgan Chase & Co. cut their target price on Chemours from $25.00 to $18.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 6th. BMO Capital Markets lifted their price target on shares of Chemours from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, October 7th. Morgan Stanley reduced their price objective on Chemours from $30.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 5th. Finally, UBS Group reduced their target price on shares of Chemours from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Chemours currently has an average rating of “Hold” and an average price target of $24.88.

Insider Transactions at Chemours

In other news, SVP Alvenia Scarborough sold 7,500 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total transaction of $154,800.00. Following the transaction, the senior vice president now directly owns 16,645 shares of the company’s stock, valued at approximately $343,552.80. This trade represents a 31.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.47% of the company’s stock.

Chemours Stock Up 3.5 %

Shares of Chemours stock opened at $21.53 on Monday. The firm has a market cap of $3.22 billion, a P/E ratio of 43.06 and a beta of 1.75. The business has a 50-day moving average price of $19.39 and a 200 day moving average price of $21.48. The company has a quick ratio of 0.92, a current ratio of 1.73 and a debt-to-equity ratio of 6.05. The Chemours Company has a fifty-two week low of $15.10 and a fifty-two week high of $32.70.

Chemours (NYSE:CC) last posted its quarterly earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.44 billion. During the same period last year, the firm posted $0.64 EPS. The company’s revenue for the quarter was up .9% on a year-over-year basis. On average, sell-side analysts forecast that The Chemours Company will post 1.35 earnings per share for the current fiscal year.

Chemours Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 15th will be given a dividend of $0.25 per share. The ex-dividend date is Friday, November 15th. This represents a $1.00 dividend on an annualized basis and a yield of 4.64%. Chemours’s dividend payout ratio is currently 200.00%.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.